It wasn't supposed to be this way: The 2017 tax cut and aggressive moves toward deregulation were supposed to pull the U.S. economy out of its glacial move higher.Economyread more
President Trump says Iran may not have intentionally downed an unmanned U.S. surveillance drone.Politicsread more
Slack pursued an unusual direct listing, meaning it did not have banks underwrite the offering.CNBC Disruptor 50read more
Slack's CEO said that the company didn't want to go public via an IPO so that it could be as transparent and accessible as possible.Deals and IPOsread more
Oil jumped as much as 6% on Thursday after Iran shot down a U.S. military drone, prompting President Trump to blast Tehran on Twitter.Energy Commoditiesread more
If Facebook cut corners in something as basic as the branding of its nascent crypto efforts, this dispute could give ammunition to its many critics.Financeread more
Workers in the gig economy could get short changed when it comes to their Social Security checks in retirement. That's because the growing ranks of people who earn money on...Personal Financeread more
CNBC analysis using Kensho found that Disney, Verizon and Home Depot were some of the best performing Dow stocks in declining-rate environments.Investingread more
For doubters thinking the rally is just a last gasp of the decadelong bull market, chart analysts are here to prove them wrong.Marketsread more
Notorious "pharma bro" Martin Shkreli has reached a settlement with his former biopharmaceutical company Retrophin to resolve "all outstanding disputes" just week after he...Biotech and Pharmaceuticalsread more
"The slowdown in the global economy is reaching this shore," veteran trader Art Cashin says.Economyread more
Gilead Sciences on Monday lowered its full-year sales outlook, citing slower-than-expected demand for its key hepatitis C drugs, and said second-quarter profits fell 22 percent.
The biotechnology company's shares, which had closed 2.3 percent higher, fell 4 percent to $85 after hours.
Product sales fell to $7.65 billion from $8.13 billion in the year-ago quarter, Gilead said in a statement. Sales of hepatitis C drugs Sovaldi and Harvoni dropped to $4 billion from $4.9 billion. Wall Street analysts, on average, had forecast hepatitis C sales of $4.09 billion, according to a poll by ISI Evercore.
Gilead lowered its 2016 product sales outlook to between $29.5 billion and $30.5 billion, from a previous range of $30 billion to $31 billion. The company said non-government U.S. health insurance plans were still limiting the number of patients who get the treatments, which many critics have said are far too expensive.
Other factors behind the lower sales forecast include weaker hepatitis C drug pricing in some European markets, a trend toward shorter treatments and the loss of market share to competition, Chief Financial Officer Robin Washington told analysts on conference call after the results were released.
Gilead drew fire more than two years ago when it charged $84,000 per course of treatment for Sovaldi, the first in a new class of hepatitis C drugs considered to be a cure for the liver-destroying disease.
The number of U.S. patients who started undergoing treatment with hepatitis C drugs was little changed from the first quarter, suggesting that the market has stabilized, ISI Group analyst Mark Schoenebaum said in a research note on Monday.
Gilead's quarterly net profit fell to $3.5 billion from $4.5 billion a year earlier. Adjusting for one-time items, Gilead earned $3.08 per share, which beat analysts' average estimate of $3.02, according to Thomson Reuters I/B/E/S.
An estimated 3.2 million Americans are infected with hepatitis C and insurers have responded by closely monitoring which patients should be treated with the new drugs.
The virus is spread by contact with contaminated blood of an infected person, by sharing needles or other equipment to inject drugs. Most patients have no symptoms, but some have fatigue, nausea, loss of appetite, and yellowing of the eyes and skin.